The Phase 3b COSMOS trial (ClinicalTrials.gov Identifier: NCT03796858) investigated guselkumab in patients with psoriatic arthritis that had an inadequate response to anti-tumor necrosis factor alpha (Anti-TNF Alpha) therapy. We were delighted to speak to Professor Laure Gossec (Pitie-Salpetriere Hospital and Sorbonne Universite, Paris, France) to discuss the findings from her analysis of the phase 3b COSMOS trial, which assessed the efficacy of guselkumab using multi-domain composite indices.
The abstract ‘Guselkumab efficacy in psoriatic arthritis assessed by multi-domain composite indices: data from the Phase 3b COSMOS trial in a TNFi-IR population.’ (Abstract number: POS1038) was presented at the European Congress of Rheumatology 2022, 1-4 June, 2022.
- What did the COSMOS study teach us about the efficacy and safety of guselkumab in patients with psoriatic arthritis who had inadequate response to tumour necrosis factor inhibitors? (0:23)
- Could you give us a brief overview of the aims and methodology of the current analysis? (1:54)
- What were the findings of the analysis and how clinically meaningful were these findings? (3:47)
- In an expanding treatment paradigm for psoriatic arthritis, what do you consider the place of guselkumab? (6:03)
Disclosures: Laure Gossec discloses consulting for AbbVie, Amgen, BMS, Celltrion, Galapagos, Gilead, GSK, Janssen, Lilly, MSD, Novartis, Pfizer, Sandoz and UCB; serving on advisory boards for Janssen; receiving honoraria from Janssen; and receiving research grants from Amgen, Galapagos, Lilly, Pfizer, Sandoz and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EULAR meeting 2022.
Share this Video
Related Videos In Psoriatic Arthritis
Laure Gossec, EULAR 2022: Guselkumab for Psoriatic Arthritis – An Analysis of the Phase 3b COSMOS Trial
The Phase 3b COSMOS trial (ClinicalTrials.gov Identifier: NCT03796858) investigated guselkumab in patients with psoriatic arthritis that had an inadequate response to anti-tumor necrosis factor alpha (Anti-TNF Alpha) therapy. We were delighted to speak to Professor Laure Gossec (Pitie-Salpetriere Hospital and Sorbonne Universite, Paris, France) to discuss the findings from her analysis of the phase 3b […]
Xenofon Baraliakos, EULAR 2022: Upadacitinib in the Treatment of Psoriatic Arthritis with Axial Involvement
Upadacitinib is an oral JAK1 inhibitor approved for the treatment of psoriatic arthritis. It was a pleasure to talk with Prof. Xenofon Baraliakos (Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany) about the impact of axial involvement on patients with psoriatic arthritis and the findings from his study investigating upadacitinib in the treatment of PsA with axial […]
Roy Fleischmann, EULAR 2022: Deucravacitinib a Tyrosine Kinase 2 Inhibitor for Psoriasis and Psoriatic Arthritis
Deucravacitinib is a tyrosine kinase 2 inhibitor currently being investigated for use in the treatment of psoriatic arthritis and in a long-term extension trial for psoriasis. It was a pleasure to talk with Prof. Roy Fleischmann (University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, USA) to learn more around the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!